Study: Self-Amplifying RNA (saRNA) “Vaccine” Trials

Simian Practicalist
Jun 12
2 min read

To those who love COVID-19 mRNA “vaccines” but don’t want the inconvenience of getting their sixth dose, there’s exciting news: human trials for the self-amplifying version (saRNA) have been conducted. Rah!!!

The saRNA “vaccine” was developed at the Imperial College London. The human trials were conducted in Uganda because Brits have the lovely tradition of testing their stuff on other people when they’re not stealing from them.

The results are published in a paper by J. Kitonsa et al titled “Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals” published on 23 May 2025.

There were 42 test subjects aged 18–45 years with a mean age of 30.2 years (SD ± 8.3 years). There were 24 male and 18 female. Two doses were administered: primary dose at week 0 and booster dose at week 4.

The most common reactions following the prime vaccination were fatigue/malaise (47.6%), headache (42.9%) and chills/shivering (40.1%). After the booster, these reactions occurred more frequently: fatigue/malaise (63.4%), headache (61.0%), and chills/shivering (58.5%).

Interestingly, the abstract states that “[n]o serious vaccine-related events occurred”. Well, that is true enough if it merely meant that no one died. But, according to Table 3 reproduced below, 39 of 41 suffered a Grade 3 adverse event, mostly Lymphopenia and Neutropenia. Grade 3 adverse events are “severe or medically significant but not immediately life-threatening”.

Unfortunately, observations regarding immunogenicity were only made up to 28 days after the booster dose. So, although almost the entire study sample had some sort of immune response, there is no available data about how antibody levels hold up or wane after a few weeks post-booster.